The Bcr-Abl inhibitor DCC-2036 inhibits necroptosis and ameliorates osteoarthritis by targeting RIPK1 and RIPK3 kinases

The Bcr-Abl inhibitor DCC-2036 inhibits necroptosis and ameliorates osteoarthritis by targeting RIPK1 and RIPK3 kinases

Osteoarthritis (OA) is a chronic progressive degenerative joint disease. Owing to its complex pathogenesis, OA treatment is typically challenging. Necroptosis is a form of programmed cell death mainly mediated by the serine/threonine kinases, RIPK1 and RIPK3, and mixed lineage kinase-like domain (ML...

Full description

Bibliographic Details
Main Authors: Longhuan Piao, Dong Wu, Chunhua Rui, Yue Yang, Shuai Liu, Jiabao Liu, Zhuangzhuang Jin, He Zhang, Xinyuan Feng, Lunhao Bai
Format: Article
Language:English
Published: Elsevier 2023-05-01
Series:Biomedicine & Pharmacotherapy
Subjects:
DCC-2036
Osteoarthritis
Chondrocyte
Necroptosis
RIPK3
RIPK1
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332223003165

Internet

http://www.sciencedirect.com/science/article/pii/S0753332223003165

Similar Items